American Journal of Kidney Diseases Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
Use of vitamin K antagonists for the prevention of stroke and systemic embolism in dialysis patients with nonvalvular atrial fibrillation is controversial. However, no good alternatives presently are available. The anti−factor Xa antagonist rivaroxaban is contraindicated for lack of pharmacokinetic, pharmacodynamic, and clinical data. This study aims to characterize the pharmacokinetics/pharmacodynamics of rivaroxaban in maintenance hemodialysis patients.http://www.ajkd.org/article/S0272-6386(15)00490-4/abstract?rss=yes
Sent with Reeder
Alberto Reino Buelvas
Médico Internista Nefrólogo
No comments:
Post a Comment